Dacin

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dacin

Property Description
Active ingredient Clindamycin Phosphate
Form Solution for injection, Topical solution, Gel, Cream
Pharmacological class Lincosamide Antibiotic
General purpose Anti-bacterial agent; Stops bacterial growth
Origin Semi-synthetic (derived from Lincomycin)

What is Dacin and its Antibiotic Class?

Dacin is a prescription-only medication featuring the active ingredient Clindamycin Phosphate, and is categorized as an antibiotic belonging to the lincosamide class. Its primary function is to serve as an anti-bacterial agent, a role clinically recognized for its utility against a wide spectrum of susceptible microbes. The active moiety, Clindamycin, is formally defined as a semi-synthetic derivative, having been chemically modified from the older lincosamide compound, Lincomycin. This classification confirms its specific action against susceptible bacteria, distinguishing its role from agents used to treat viral or fungal infections. Clindamycin maintains an established role in combating a variety of bacterial infections.

Composition: Clindamycin Phosphate as a Prodrug

The preparation utilizes Clindamycin Phosphate, which operates as an inactive prodrug; its chemical structure, defined as a water-soluble ester, requires subsequent biological activation. Upon administration, the compound undergoes rapid in vivo hydrolysis within the body to successfully yield the therapeutically potent molecule, Clindamycin. This conversion process is essential, as the active Clindamycin is what directly mediates the anti-microbial effect. The high-level action of the medicine is primarily bacteriostatic, meaning it prevents bacterial growth and proliferation.

Available Forms and General Purpose

Formulations containing Clindamycin Phosphate are available in diverse dosage forms tailored for different routes of administration, which include a solution for injection for parenteral use, alongside topical gel, cream, and topical solution preparations. The availability of multiple pharmaceutical preparations reflects its broad utility, allowing for either local application to the affected site or systemic delivery for pervasive infections. The overarching general purpose of Dacin is to help the body successfully resolve certain bacterial infections by inhibiting bacterial protein synthesis, a mechanism frequently studied in infectious disease research.

Regulatory References

  1. Clindamycin Drug Information
  2. WHO Essential Medicines List for Clindamycin

What side effects are possible with Dacin?

Possible side effects and safety information

Dacin's safety profile is primarily characterized by the officially documented, dose-dependent suppression of blood cell formation and potential for severe organ toxicity.

Adverse Reaction Scope

Classification System/Organ Class (SOC) Focus
Very Common (more than 1 in 10 patients) Blood and Lymphatic System Disorders (e.g., anemia, neutropenia, thrombocytopenia, leukopenia); Gastrointestinal Disorders (e.g., nausea, vomiting, mucositis, stomatitis, esophagitis); Skin and Subcutaneous Tissue Disorders (e.g., alopecia, rash).
Serious Adverse Reactions (documented) Hepatotoxicity (including fatal hepatic veno-occlusive disease); Severe Myelosuppression; Severe Mucocutaneous Reactions (e.g., Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis); Infections/Sepsis.

Safety-Related Restrictions and Considerations

Population-Specific Safety: The medicine is contraindicated in pregnancy due to the potential for fetal harm and is also contraindicated during breastfeeding. Caution and dose adjustment are required for patients with pre-existing liver or kidney impairment.

Exposure and Administration Limits: The risk of veno-occlusive disease is increased in young children and with concomitant or prior radiotherapy. Severe local tissue injury (extravasation) can occur if the injection leaks outside the vein. Administration should be strictly limited to the supervision of qualified practitioners with experience in cytotoxic chemotherapy.

Monitoring: Regulatory requirements mandate close monitoring of complete blood counts and liver function tests before and during each cycle of administration to detect severe, potentially fatal toxicities promptly.

Overdose and Emergency Response

Overdose and When to Seek Help

Documented Overdose Manifestations

Overdose of Dacin (Clindamycin Phosphate) is primarily characterized by an increased incidence of gastrointestinal side effects, including nausea, vomiting, and abdominal pain. Severe and potentially life-threatening outcomes reported in regulatory documents include cardiopulmonary arrest and hypotension, particularly following too rapid intravenous administration. Additional severe outcomes include Acute Kidney Injury.


Severe Outcomes Requiring Immediate Action

Immediate medical help is required upon suspected overdose or the onset of severe systemic events. These include fatal colitis (due to C. difficile), anaphylactic shock, and severe immunologic skin reactions such as Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). Official guidance mandates that individuals must seek immediate medical attention, call emergency services, or contact a Poison Control center. Treatment should be immediately discontinued if signs of severe hypersensitivity occur.


Management and Regulatory Constraints

No specific antidote is known for Clindamycin overdose. Official documentation confirms that hemodialysis and peritoneal dialysis are ineffective for systemic drug removal, meaning management is strictly symptomatic and supportive. Special consideration is necessary for elderly patients and individuals with hepatic or renal impairment, as they may face a greater risk of adverse reactions or drug accumulation due to a prolonged elimination half-life.

Therapeutic Uses of Dacin

What Dacin Treats: Main Uses and Benefits

Dacin is used in situations involving certain distressing symptoms where acute or chronic manifestations create noticeable physiological strain. Dacin is relevant within therapeutic areas aligned with established clinical categories where additional symptomatic support is applied.

The medication is commonly used to help with conditions presenting with musculoskeletal pain, physical stiffness, and inflammatory symptoms such as swelling and tenderness. It is applied in clinical settings where supportive symptom management is appropriate during challenging episodes, such as symptomatic flare-ups or periods of increased distress.

“Dacin supports the patient during difficult episodes by easing distress and assists with maintaining functional stability.”

By managing symptom clusters that may intensify over time, Dacin contributes to improved comfort during these periods and may help patients cope more steadily with symptom fluctuations. This supportive role is considered relevant when symptoms create noticeable interference with routine activities.


Quick Fact: Symptom Focus: Inflammatory States

Eligibility and Restrictions for Use

Official Regulatory Eligibility for DACIN (Dacarbazine)

The official eligibility profile for DACIN, which contains the active substance dacarbazine, is strictly defined by government regulatory documents based on pre-existing health conditions, immunological status, and physiological states. This medicine is administered only under the supervision of a physician experienced in cancer chemotherapeutic agents.

Populations for Whom Use is CONTRAINDICATED Condition-Specific Restrictions
Patients with known hypersensitivity to dacarbazine. Severe liver or kidney diseases.
Pregnant or breastfeeding women. Leukopenia and/or thrombocytopenia.
Patients who have previously had severe myelosuppression. History of veno-occlusive disease of the liver (if developed during treatment).

Additional Non-Eligibility and Restriction Rules

Use is not recommended or requires special consideration in patients with acute infections and those receiving a live-attenuated vaccine, which should be avoided due to the immunosuppressive effects of the medicine. The concomitant use of this medication with the yellow fever vaccine is specifically contraindicated in official labeling. Furthermore, the safety and efficacy of dacarbazine in the pediatric population (children/adolescents under 15 years) have not yet been established. The strict contraindications are based on high-risk factors for toxicity, including severe bone marrow or organ dysfunction.

What should I know about interactions with other medicines?

Dacin Interactions with other medicines and products

Official regulatory documentation details specific interaction patterns for Dacin (Clindamycin) with other medicinal products, primarily classified based on pharmacokinetic and pharmacodynamic effects.

Interaction Restrictions and Contraindications

Regulatory labels establish that co-administration with the macrolide antimicrobial Erythromycin should not occur. This restriction is based on documented in vitro antagonism between the two substances.

Pharmacokinetic Interactions (CYP Enzyme System)

The medicine is subject to metabolic interactions involving the Cytochrome P450 (CYP) enzyme system, specifically CYP3A4 and/or CYP3A5. The regulatory profile notes the following outcomes:

  • Co-administration with strong CYP3A4/3A5 inducers (e.g., Rifampicin) may increase Clindamycin clearance, potentially resulting in reduced systemic exposure.
  • Co-administration with strong CYP3A4/3A5 inhibitors may reduce Clindamycin clearance, leading to potentially increased systemic exposure of Clindamycin.

Pharmacodynamic Interactions

Clindamycin has intrinsic neuromuscular blocking properties and can enhance the action of other Neuromuscular Blocking Agents. Additionally, increases in coagulation tests (INR/PT) and/or bleeding have been reported with the co-administration of Vitamin K Antagonists (e.g., Warfarin).

Mechanism of Action

How Dacin Works

Dacin's mechanism of action is primarily focused on inhibiting bacterial protein synthesis through highly specific binding. The active molecule, Clindamycin, targets the 50S ribosomal subunit of susceptible bacteria, engaging a site on the 23S Ribosomal RNA near the peptidyl transferase center. This binding physically blocks the translocation step necessary for peptide chain elongation, functionally arresting bacterial proliferation, which constitutes its mathbfbacteriostatic effect.

Beyond growth inhibition, the mechanism extends to suppressing the synthesis of specific virulence factors, such as lipases and protein toxins, through the same ribosomal interference. This secondary action results in the suppression of inflammatory factor synthesis by the pathogen. Mechanistic constraints include intrinsic resistance in many Gram-negative aerobic bacteria due to their outer membrane barrier, and acquired mathbfMLSB cross-resistance caused by enzymatic mathbfmethylation of the ribosomal binding site, which renders the target inaccessible to Clindamycin.

Dosage and Administration Information

Dacin (Clindamycin Phosphate) is administered through multiple official routes, which include oral (capsules, solution), parenteral (Intravenous, Intramuscular), topical, and intravaginal preparations, depending on the required site of action.

Administration and Dosing Regimens

The dosage and schedule are determined by the severity of the infection and the patient's age. For adults, systemic use is typically dosed every 6 to 8 hours. The standard parenteral dose ranges from 600 mg to 2700 mg per day in 2 to 4 equal doses, with a maximum of 4800 mg/day for life-threatening situations. Pediatric systemic dosing is weight-based, typically between 8 mg/kg/day and 25 mg/kg/day in 3 or 4 equal doses.

Key Instructions for Proper Use

Administration Method Procedural Constraint
Oral Capsules Must be taken with a full glass of water to prevent irritation of the esophagus.
Intravenous (IV) Must be diluted prior to infusion. The infusion rate must not exceed 30 mg/min to prevent adverse reactions.
Intramuscular (IM) A single IM injection should not exceed 600 mg.

For systemic infections involving beta-hemolytic streptococci, the course of treatment must be continued for a minimum of 10 days. Dosage adjustments are generally not required for patients with mild to moderate renal or hepatic impairment.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Dacin


Evidence for Use in Serious Systemic Bacterial Infections

Dacin was studied in Randomized Controlled Trials (RCTs) and meta-analyses to examine its use against serious internal infections, particularly those caused by susceptible anaerobic bacteria and specific Gram-positive cocci. Studies examined core outcomes such as clinical cure—the resolution of infection signs—and the microbiological eradication of the disease-causing organism from the infection site.

Studies exploring this use reported measurements of clinical cure that were consistent with patterns observed in trials involving alternative, established antibiotic treatments. Research also described that the findings related to patient survival rates were consistent with expectations for patients treated for severe infections where the organism was susceptible.

Evidence for Skin and Soft Tissue Infections

The research examined Dacin's role in treating uncomplicated skin and soft tissue infections (SSTIs) and extensively explored its use in managing acne vulgaris. For acne, numerous placebo-controlled trials were conducted, mainly involving adults and adolescents, comparing the topical solution or gel to a non-medicated control. For SSTIs, studies often monitored Dacin alongside other established oral antibiotics.

In studies focusing on acne, researchers quantified outcomes by measuring changes in the number of lesions. Research on SSTIs described that studies monitored clinical resolution in patients receiving Dacin alongside patients receiving active comparator antibiotics. These studies generally monitored responses over intermediate time intervals, typically lasting 8 to 12 weeks for acne trials.

Evidence for Bacterial Vaginosis (BV)

Dacin was studied for the treatment of Bacterial Vaginosis (BV) using both intravaginal and oral formulations. The research included Randomized Controlled Trials (RCTs) that monitored Dacin against a placebo and other standard treatments, involving both nonpregnant women and a smaller number of pregnant women. Researchers primarily measured clinical cure (the resolution of symptoms) and microbiological cure (the successful normalization of the vaginal flora).

Findings describe measurements of both clinical and microbiological cure, with studies documenting the evolution of symptoms in the Dacin group alongside the placebo group. Research also highlights that BV has a high natural recurrence rate, a factor that was monitored across all trials.

What is Still Uncertain About Dacin's Research Record

Research indicates that there are several key areas where the evidence remains limited or uncertain. One major area is the impact of rising antibiotic resistance across different organisms and geographical regions, which may affect the certainty of future measurements of efficacy. Furthermore, long-term outcomes are not well characterized, as most trials monitored patients only over defined time intervals that do not extend for years. Comparative evidence is sometimes lacking or heterogeneous, especially when evaluating Dacin alongside newer classes of antibiotics. Overall, the available evidence is continually updated as new studies are conducted, and research provides context but not individual predictions about personal outcomes.

Key Studies & References

  1. Treatment of pregnant women with asymptomatic bacterial vaginosis with clindamycin - Norwegian Institute of Public Health (FHI)
  2. Randomized, Double-Blind Trial of Clindamycin, Trimethoprim-Sulfamethoxazole, or Placebo for Uncomplicated Skin and Soft Tissue Infections (NCT00730028) - ClinicalTrials.gov
  3. Study Evaluating Tigecycline Versus Clindamycin Or Vancomycin on Complicated Skin And Skin Structure Infections (NCT00911573) - ClinicalTrials.gov

Frequently Asked Questions (FAQ)

Common questions about Dacin (FAQ)


Q: How long does it usually take for Dacin to start working?

Studies and official product information indicate that peak concentrations of the active medicine are reached quickly after administration. However, regulatory information suggests that it may take up to 48 hours for the symptoms related to the underlying infection to show noticeable improvement.


Q: Does Dacin affect sleep patterns?

Official information does not commonly cite drowsiness as a direct side effect of Dacin itself. Feeling generally fatigued or tired, however, may be a symptom of the underlying infection being treated.


Q: Is Dacin considered safe for older adults?

Pharmacokinetic studies show that age alone, specifically in older adults, does not significantly change how the body processes the medicine. Therefore, a standard dosage adjustment is typically not required based on age alone, though other pre-existing health conditions may be a factor.


Q: Can Dacin be taken with standard pain relievers like ibuprofen?

Regulatory sources generally do not cite a direct, specific interaction between Dacin (Clindamycin) and standard non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen. The decision regarding the combined use of medicines is typically evaluated by a healthcare professional.


Q: Do I need a special diet while using Dacin?

Regulatory documents state that the absorption of oral Dacin (Clindamycin) is generally not altered by the presence of food. Therefore, a specific or restrictive diet is generally not described as necessary for the medicine to be absorbed.


Q: What happens if I miss a dose of Dacin?

According to the official patient information, if a dose is missed by only a few hours, official instructions often describe that it may still be taken. If it is nearly time for the next scheduled dose, the missed dose should be skipped; a double dose must not be taken to try to make up for the one that was missed.


Q: How long does Dacin stay in the body after I stop taking it?

Official information describes that the active form of the medicine has an average elimination half-life of about 3 hours in adults. This is the time it takes for the concentration of the medicine in the body to be reduced by half.


Q: Is it normal to feel tired or fatigued when first starting Dacin?

Feeling tired or fatigued is not listed among the most common adverse reactions. However, fatigue can be a general symptom of the infection being treated, and it is also listed as a potential symptom of a serious side effect, such as Clostridioides difficile-associated diarrhea, which warrants review by a healthcare professional.


Q: Does Dacin have a 'black box' warning, and what does that mean?

The medicine does carry a Boxed Warning, sometimes referred to as a 'black box' warning, in official documents. This warning highlights the risk of severe Clostridioides difficile-associated diarrhea (CDAD), which can range from mild diarrhea to a serious, potentially fatal inflammation of the colon.


Q: Can Dacin cause mood changes or emotional side effects?

Mood or emotional side effects, including reports of agitation, confusion, and depression, have been documented as potential side effects. The precise incidence of these emotional effects is not clearly known from official data.


Q: Are there any known interactions between Dacin and alcohol consumption?

Official and supporting patient information does not report a dangerous interaction with alcohol. However, consuming alcohol may potentially worsen common gastrointestinal side effects of Dacin, such as nausea or vomiting.


Q: Is Dacin considered safe for individuals with pre-existing heart conditions?

Studies have examined the use of Dacin (Clindamycin) as an alternative antibiotic for certain high-risk heart patients who may be allergic to penicillin. Its inclusion in these guidelines suggests it is generally appropriate for use in patients with these underlying heart conditions.


Q: What should I do if a side effect of Dacin feels severe?

According to regulatory patient tips, if a severe side effect develops, such as severe or persistent diarrhea or a serious, widespread skin rash, official patient information states that in such cases, discontinuation of the medicine may be necessary. Such an event warrants prompt consultation with a healthcare professional.


Q: What are the typical expectations for managing the condition while on Dacin?

Official documents describe that Dacin is intended to be taken exactly as prescribed by a healthcare professional. Finishing the entire prescribed course of treatment is a key expectation for successfully addressing the infection, even if symptoms begin to improve quickly.


Q: Does Dacin interfere with birth control pills?

Studies and regulatory documents suggest that Dacin (Clindamycin) may reduce the effectiveness of some birth control pills, specifically those containing ethinyl estradiol. This potential interaction may lead to an increased risk of pregnancy or breakthrough bleeding.


Q: Does the time of day matter when taking Dacin?

Oral capsules may be taken either before or after a meal, according to the official product information. The focus of administration is on taking the dose with a full glass of water and strictly maintaining the correct interval (e.g., every 6 or 8 hours).


Q: What happens if Dacin is stopped suddenly?

Official patient information states that stopping the medicine too soon may allow the original infection to return or worsen. Any alteration to the prescribed regimen is intended to be made under the direct guidance of a healthcare professional.


Q: Does Dacin cause dry mouth or changes in taste?

Gastrointestinal side effects, which are commonly reported, can include a metallic or bitter taste in the mouth. Dry mouth has also been documented, although the exact frequency is not precisely known.


Q: Can taking Dacin make someone more sensitive to the sun?

Official information indicates that both the topical and oral forms of Dacin (Clindamycin) can increase the body's sensitivity to the sun, a reaction known as photosensitivity. During treatment, minimizing sun exposure and utilizing appropriate sun protection measures is generally described as appropriate.


Q: What is the purpose of the inactive ingredients in Dacin?

Inactive ingredients are listed in official drug labeling and serve important roles in the preparation of the medicine. Their purpose includes preserving the drug, ensuring the correct color and texture, and helping to form the capsule or solution.


Q: Are generic versions of Dacin available, and are they the same?

Dacin (Clindamycin) is widely available in generic form for many of its common formulations. Official standards require that generic medicines be therapeutically equivalent to the brand-name product, meaning they are intended to work the same way in the body.


Q: How often do the official safety labels for Dacin get updated?

Official drug labels are updated periodically by regulatory bodies as new safety and efficacy data become available from ongoing research. These updates ensure that the information reflects the most current understanding of the medicine.

How should Dacin be stored and disposed of?

How to Store and Dispose of Dacin

Official regulatory guidelines establish specific requirements for storing and discarding Dacin (Clindamycin Phosphate) to maintain its stability.

Storage and Handling

  • Temperature: Store Dacin preparations, including sterile solutions and topical forms, at Controlled Room Temperature (typically 20 C to 25 C). It is mandatory to protect all forms from freezing.
  • Protection: Keep the medicine out of the reach and sight of children. Topical solutions and foams are flammable and must be kept away from heat and open flames.
  • Packaging: Store the product in its original, tightly closed container and protect it from light.
  • Stability: Single-use injectable forms must be used immediately upon opening. Unused portions of multi-dose vials or diluted solutions must be discarded within the mandated time frame (e.g., 24 hours).

Disposal

  • Official Rules: Unused or expired Dacin must not be disposed of via household waste or wastewater.
  • Procedure: Dispose of the product in accordance with local requirements for pharmaceutical waste, often requiring return to a pharmacy or designated collection site.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dacin found in:

A-Z Index: